In summary, this study underscores the prognostic significance of both clinical and inflammatory parameters, particularly BMI, CEA, SII, and CIPI, in patients with pMMR advanced CRC receiving immunotherapy combined with targeted therapy. The gene discussed is CEACAM5; the disease is colorectal carcinoma.